1-5 of 5
Rachelle Perea
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Tatyana Feldman, Enrica Marchi, Stephen D. Smith, Adam J. Olszewski, Auris O Huen, Zachary D. Epstein-Peterson, Don A. Stevens, Alexander N. Starodub, Eric J. Feldman, Cristina P Rodriguez, John C. Reneau, Jonathan E. Brammer, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Patrick Henrick, Joyoti Dey, Alyssa Fasciano, Rahul Karnik, Sagar Agarwal, Ashwin Gollerkeri, Jared Gollob, Aditi Shastri, Stefan K. Barta
Journal: Blood
Blood (2024) 144 (Supplement 1): 4433.
https://doi.org/10.1182/blood-2024-210301
Published: 2024
Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Aditi Shastri, Eric J Feldman, Alexander N Starodub, Tatyana Feldman, Cristina P Rodriguez, Zachary D. Epstein-Peterson, Don A. Stevens, Adam J Olszewski, Auris O Huen, Pierluigi Porcu, John C Reneau, Stefan K. Barta, Enrica Marchi, Ahmad H Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, Stephen D Smith
Journal: Blood
Blood (2023) 142 (Supplement 1): 3081.
https://doi.org/10.1182/blood-2023-181130
Published: 2023
Journal Articles

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jennifer Kimberly Lue, Don A. Stevens, Michael E. Williams, Jason Westin, Reggie Ewesuedo, Alice McDonald, Sagar Agarwal, Patrick Henrick, Rachelle Perea, Jared Gollob
Journal: Blood
Blood (2022) 140 (Supplement 1): 12143–12144.
https://doi.org/10.1182/blood-2022-170151
Published: 2022
Journal Articles

A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Stephen D Smith, Alexander Starodub, Don A. Stevens, Aditi Shastri, Pierluigi Porcu, Tatyana Feldman, Reggie Ewesuedo, Chris DeSavi, Joyoti Dey, Sagar Agarwal, Sean Donohue, Rachelle Perea, Christine Klaus, Jared Gollob
Journal: Blood
Blood (2022) 140 (Supplement 1): 12024–12025.
https://doi.org/10.1182/blood-2022-169514
Published: 2022
Journal Articles

Evaluation of Humoral Immune Responses to Vaccination with Tetanus Toxoid and KLH in Rituximab-Treated Follicular Non-Hodgkin’s Lymphoma Patients Compared to Healthy Volunteers

M. Wayne Saville, MD, FACP, FRCPA, Nancy Valente, MD, Rachelle Perea, Kye Gilder, Judith Berlfein, Ilya Zyuzgin, PhD, David Belada, MD., PhD., Andre Banat, MD, MBA, Tudor Ciuleanu, MD
Journal: Blood
Blood (2008) 112 (11): 3066.
https://doi.org/10.1182/blood.V112.11.3066.3066
Published: 2008